Theranostics for Triple-Negative Breast Cancer.

Area of Science:

• Oncology
• Nanotechnology
• Pharmacology

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis and limited treatment options.
• Current therapies like endocrine or anti-HER2 treatments are ineffective for TNBC.
• Disease heterogeneity leads to variable responses to chemotherapy.

Purpose of the Study:

• To review recently FDA-approved targeted therapies for TNBC.
• To discuss novel theranostic nanocarrier approaches for TNBC diagnosis and treatment.
• To provide an overview of nano-therapeutic modalities in TNBC management.

Main Methods:

• Literature review of FDA-approved targeted therapies for TNBC.
• Exploration of recent advancements in nanocarrier-based theranostics.
• Summary of lipid-based, polymer-based, and carbon-based nanocarrier systems.

Main Results:

• FDA-approved targeted therapies for TNBC include PARP inhibitors, checkpoint inhibitors, and antibody-drug conjugates.
• Nanoparticle-based theranostics offer simultaneous drug delivery and lesion visualization.
• Various nanocarrier platforms show promise for targeted TNBC treatment with reduced toxicity.

Conclusions:

• Targeted therapies and nanotheranostics represent promising strategies to improve TNBC outcomes.
• Nanocarrier-based theranostics enable precise drug delivery and real-time monitoring.
• Further research into nano-therapeutic modalities is crucial for advancing TNBC care.